» Articles » PMID: 28266614

A Multi-component Classifier for Nonalcoholic Fatty Liver Disease (NAFLD) Based on Genomic, Proteomic, and Phenomic Data Domains

Overview
Journal Sci Rep
Specialty Science
Date 2017 Mar 8
PMID 28266614
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of conditions that include steatohepatitis and fibrosis that are thought to emanate from hepatic steatosis. Few robust biomarkers or diagnostic tests have been developed for hepatic steatosis in the setting of obesity. We have developed a multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and proteomic variables using data from 576 adults with extreme obesity who underwent bariatric surgery and intra-operative liver biopsy. Using a 443 patient training set, protein biomarker discovery was performed using the highly multiplexed SOMAscan proteomic assay, a set of 19 clinical variables, and the steatosis predisposing PNPLA3 rs738409 single nucleotide polymorphism genotype status. The most stable markers were selected using a stability selection algorithm with a L-regularized logistic regression kernel and were then fitted with logistic regression models to classify steatosis, that were then tested against a 133 sample blinded verification set. The highest area under the ROC curve (AUC) for steatosis of PNPLA3 rs738409 genotype, 8 proteins, or 19 phenotypic variables was 0.913, whereas the final classifier that included variables from all three domains had an AUC of 0.935. These data indicate that multi-domain modeling has better predictive power than comprehensive analysis of variables from a single domain.

Citing Articles

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E Int J Mol Sci. 2025; 26(4).

PMID: 40004054 PMC: 11855544. DOI: 10.3390/ijms26041589.


Label-Free Proteomics of Severe Acute Hepatitis of Unknown Origin in Children by High-Resolution Mass Spectrometry.

de Farias J, de Lima Vitorino M, Martins Esteves F, Fonseca Lima E, da Silva R, de Lima Filho J ACS Omega. 2025; 9(51):50685-50694.

PMID: 39741806 PMC: 11684528. DOI: 10.1021/acsomega.4c08745.


Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives.

Zhu Z, Chen Y, Qin X, Liu S, Wang J, Ren H Smart Med. 2024; 2(2):e20220029.

PMID: 39188279 PMC: 11236021. DOI: 10.1002/SMMD.20220029.


Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.

Ghosh S, Zhao X, Alim M, Brudno M, Bhat M Gut. 2024; 74(2):295-311.

PMID: 39174307 PMC: 11874365. DOI: 10.1136/gutjnl-2023-331740.


Serum proteome signatures associated with liver steatosis in adolescents with obesity.

Giraudi P, Pascut D, Banfi C, Ghilardi S, Tiribelli C, Bondesan A J Endocrinol Invest. 2024; 48(1):213-225.

PMID: 39017916 PMC: 11729140. DOI: 10.1007/s40618-024-02419-x.


References
1.
Flechtner-Mors M, Schick A, Oeztuerk S, Haenle M, Wilhelm M, Koenig W . Associations of fatty liver disease and other factors affecting serum SHBG concentrations: a population based study on 1657 subjects. Horm Metab Res. 2013; 46(4):287-93. DOI: 10.1055/s-0033-1354369. View

2.
Lazo M, Zeb I, Nasir K, Tracy R, Budoff M, Ouyang P . Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol. 2015; 13(9):1686-93.e2. PMC: 4500744. DOI: 10.1016/j.cgh.2014.12.033. View

3.
Voyle N, Baker D, Burnham S, Covin A, Zhang Z, Sangurdekar D . Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis. 2015; 46(4):947-61. PMC: 4923714. DOI: 10.3233/JAD-150020. View

4.
Speliotes E, Butler J, Palmer C, Voight B, Hirschhorn J . PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010; 52(3):904-12. PMC: 3070300. DOI: 10.1002/hep.23768. View

5.
Hardy T, Oakley F, Anstee Q, Day C . Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annu Rev Pathol. 2016; 11:451-96. DOI: 10.1146/annurev-pathol-012615-044224. View